ReviewCancers2023
Surgery for Solitary Fibrous Tumors of the Pleura: A Review of the Available Evidence.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Solitary fibrous tumour of the pleura: evolution in surgical management and challenges in prognostic evaluation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Recurrent Pleural Solitary Fibrous Tumor: A Case Report and Brief Literature Review.Reports (MDPI) · 2026Article
- The Silent Intruder: A Case Report of an Incidentally Discovered Solitary Fibrous Tumor of the Lung.Cureus · 2026Article
- Perioperative Decision-Making for a Solitary Fibrous Tumor of the Pleura: Lessons from Two Cases and Current Evidence.Diagnostics (Basel, Switzerland) · 2026Article
- Effectiveness of classification and scoring systems in solitary fibrous tumor prognosis prediction.Pakistan journal of medical sciences · 2026Article
- Article
- Hybrid video-assisted thoracoscopic resection of a massive mediastinal solitary fibrous tumor: overcoming challenges: a case report.Journal of medical case reports · 2025Article
- Case of a Large Solitary Fibrous Tumour of the Pleura Complicated by Empyema.Respirology case reports · 2025Article
- Solitary fibrous tumor of the chest wall with Doege-Potter syndrome: a case report.Frontiers in oncology · 2025Article
- Case Report: Doege-Potter syndrome: a giant solitary fibrous pleural tumor causing severe hypoglycemia.Frontiers in oncology · 2025Article
- Ruptured solitary fibrous tumor of the pleura with hemothorax: a case report.Surgical case reports · 2024Article
- Malignant Solitary Fibrous Tumor of the Mediastinum with Multiple Recurrences and a Rare Metastasis to the Thyroid Gland: A Case Report.Journal of chest surgery · 2024Article
- Resection of pleural solitary fibrous tumors with distinct feeding vessels arising from the descending aorta: a case report.Journal of cardiothoracic surgery · 2024Article
- Case report: A case of giant malignant solitary fibrous tumor of the pleura with Doege-Potter's syndrome and review of the literature.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary fibrous tumors of the pleura (pSFT) are a relatively rare neoplasms that can arise from either visceral or parietal pleura and may have different aggressive biological behaviors. Surgery is well known to be the cornerstone of the treatment for pSFT. We reviewed the existing literature, focusing on the role of surgery in the management and treatment of pSFT. All English-written literature has been reviewed, focusing on those reporting on the perioperative management and postoperative outcomes. Surgery for pSFT is feasible and safe in all experiences reported in the literature, but surgical approaches and techniques may vary according to the tumor dimensions, localization, and surgeons' skills. Long-term outcomes are good, with a 10-year overall survival rate of more than 70% in most of the reported experiences; on the other hand, recurrence may happen in up to 17% of cases, which occurs mainly in the first two years after surgery, but case reports suggest the need for a longer follow-up to assess the risk of late recurrence. Malignant histology and dimensions are the most recognized risk factors for recurrence. Recurrence might be operated on in select patients. Surgery is the treatment of choice in pSFT, but a radical resection and a careful postoperative follow-up should be carried out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.